These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

288 related items for PubMed ID: 22728515

  • 1. Size-controlled, dual-ligand modified liposomes that target the tumor vasculature show promise for use in drug-resistant cancer therapy.
    Takara K, Hatakeyama H, Kibria G, Ohga N, Hida K, Harashima H.
    J Control Release; 2012 Aug 20; 162(1):225-32. PubMed ID: 22728515
    [Abstract] [Full Text] [Related]

  • 2. Design of a dual-ligand system using a specific ligand and cell penetrating peptide, resulting in a synergistic effect on selectivity and cellular uptake.
    Takara K, Hatakeyama H, Ohga N, Hida K, Harashima H.
    Int J Pharm; 2010 Aug 30; 396(1-2):143-8. PubMed ID: 20457236
    [Abstract] [Full Text] [Related]

  • 3. A new peptide motif present in the protective antigen of anthrax toxin exerts its efficiency on the cellular uptake of liposomes and applications for a dual-ligand system.
    Kibria G, Hatakeyama H, Harashima H.
    Int J Pharm; 2011 Jun 30; 412(1-2):106-14. PubMed ID: 21414394
    [Abstract] [Full Text] [Related]

  • 4. The effect of liposomal size on the targeted delivery of doxorubicin to Integrin αvβ3-expressing tumor endothelial cells.
    Kibria G, Hatakeyama H, Ohga N, Hida K, Harashima H.
    Biomaterials; 2013 Jul 30; 34(22):5617-27. PubMed ID: 23623323
    [Abstract] [Full Text] [Related]

  • 5. APN/CD13-targeting as a strategy to alter the tumor accumulation of liposomes.
    Dunne M, Zheng J, Rosenblat J, Jaffray DA, Allen C.
    J Control Release; 2011 Sep 25; 154(3):298-305. PubMed ID: 21640146
    [Abstract] [Full Text] [Related]

  • 6. Binding and internalization of NGR-peptide-targeted liposomal doxorubicin (TVT-DOX) in CD13-expressing cells and its antitumor effects.
    Garde SV, Forté AJ, Ge M, Lepekhin EA, Panchal CJ, Rabbani SA, Wu JJ.
    Anticancer Drugs; 2007 Nov 25; 18(10):1189-200. PubMed ID: 17893520
    [Abstract] [Full Text] [Related]

  • 7. PEGylated liposomes with NGR ligand and heat-activable cell-penetrating peptide-doxorubicin conjugate for tumor-specific therapy.
    Yang Y, Yang Y, Xie X, Cai X, Zhang H, Gong W, Wang Z, Mei X.
    Biomaterials; 2014 May 25; 35(14):4368-81. PubMed ID: 24565519
    [Abstract] [Full Text] [Related]

  • 8. Tumor targeting of doxorubicin by anti-MT1-MMP antibody-modified PEG liposomes.
    Hatakeyama H, Akita H, Ishida E, Hashimoto K, Kobayashi H, Aoki T, Yasuda J, Obata K, Kikuchi H, Ishida T, Kiwada H, Harashima H.
    Int J Pharm; 2007 Sep 05; 342(1-2):194-200. PubMed ID: 17583453
    [Abstract] [Full Text] [Related]

  • 9. Dual-modified liposomes with a two-photon-sensitive cell penetrating peptide and NGR ligand for siRNA targeting delivery.
    Yang Y, Yang Y, Xie X, Wang Z, Gong W, Zhang H, Li Y, Yu F, Li Z, Mei X.
    Biomaterials; 2015 Apr 05; 48():84-96. PubMed ID: 25701034
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Anti-tumor effect via passive anti-angiogenesis of PEGylated liposomes encapsulating doxorubicin in drug resistant tumors.
    Kibria G, Hatakeyama H, Sato Y, Harashima H.
    Int J Pharm; 2016 Jul 25; 509(1-2):178-187. PubMed ID: 27234700
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Vascular damage and anti-angiogenic effects of tumor vessel-targeted liposomal chemotherapy.
    Pastorino F, Brignole C, Marimpietri D, Cilli M, Gambini C, Ribatti D, Longhi R, Allen TM, Corti A, Ponzoni M.
    Cancer Res; 2003 Nov 01; 63(21):7400-9. PubMed ID: 14612539
    [Abstract] [Full Text] [Related]

  • 16. A specific peptide ligand-modified lipid nanoparticle carrier for the inhibition of tumor metastasis growth.
    Wang Z, Yu Y, Dai W, Cui J, Wu H, Yuan L, Zhang H, Wang X, Wang J, Zhang X, Zhang Q.
    Biomaterials; 2013 Jan 01; 34(3):756-64. PubMed ID: 23117217
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Improved tumor-targeting drug delivery and therapeutic efficacy by cationic liposome modified with truncated bFGF peptide.
    Chen X, Wang X, Wang Y, Yang L, Hu J, Xiao W, Fu A, Cai L, Li X, Ye X, Liu Y, Wu W, Shao X, Mao Y, Wei Y, Chen L.
    J Control Release; 2010 Jul 01; 145(1):17-25. PubMed ID: 20307599
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Tumor vascular targeting with tumor necrosis factor alpha and chemotherapeutic drugs.
    Corti A, Ponzoni M.
    Ann N Y Acad Sci; 2004 Dec 01; 1028():104-12. PubMed ID: 15650236
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.